Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

Benzinga · 03/21 17:57
Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $9 to $4.5.